Nature子刊：华科谭磊/杨操团队开发超声增强的广谱抗菌肽，治疗抗生素耐药菌感染

Core Viewpoint - The article discusses the development of a novel ultrasound-sensitive broad-spectrum antimicrobial peptide based on diphenylalanine, which shows high efficacy against drug-resistant bacteria and offers a promising strategy for treating infections caused by antibiotic-resistant pathogens [1][2][9]. Group 1: Antimicrobial Resistance and Challenges - Overuse of antibiotics has led to an increase in drug-resistant pathogens, making infections harder to treat and posing significant health risks globally [1]. - Traditional antimicrobial peptides (AMPs) have limitations, including slow antibacterial effects, rapid biodegradation, non-selective toxicity, and short retention time at infection sites [4]. Group 2: Research Findings - The research team developed a short peptide that is activated by ultrasound, achieving over 99% antibacterial efficiency against clinical isolates of methicillin-resistant bacteria within 15 minutes of ultrasound exposure, while exhibiting low toxicity [5][6]. - Seven short peptides were designed, with one specific peptide (FFRK8) demonstrating satisfactory antibacterial performance and biocompatibility under ultrasound activation [6]. Group 3: Clinical Implications - In a goat model of difficult-to-treat intervertebral disc infection, FFRK8 outperformed the potent antibiotic vancomycin, indicating its potential for clinical applications [7]. - The study suggests that ultrasound-activated antimicrobial peptides could provide an effective treatment for deep infections with poor vascular distribution, addressing the challenge of antibiotic resistance [9].